================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 3)*
Acadia Pharmaceuticals Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.0001 par value per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
004225108
- --------------------------------------------------------------------------------
(CUSIP Number)
December 31, 2007
- --------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[_] Rule 13d-1(b)
[_] Rule 13d-1(c)
[X] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
================================================================================
==================== =============
CUSIP NO. 004225108 13G PAGE 2 OF 16
==================== =============
================================================================================
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
OXFORD BIOSCIENCE PARTNERS IV L.P.
- ----- -------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)(a)[_]
(b)[_]
- ----- -------------------------------------------------------------------------
3 SEC USE ONLY
- ----- -------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
0
----- --------------------------------------------------------
NUMBER OF 6 SHARED VOTING POWER
SHARES
BENEFICIALLY 3,422,717
OWNED BY ----- --------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 0
WITH: ----- --------------------------------------------------------
8 SHARED DISPOSITIVE POWER
3,422,717
- ----- -------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,422,717
- ----- -------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [_]
- ----- -------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.3%
- ----- -------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN
================================================================================
Page 2 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 3 OF 16
==================== =============
================================================================================
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
mRNA FUND II L.P.
- ----- -------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)(a)[_]
(b)[_]
- ----- -------------------------------------------------------------------------
3 SEC USE ONLY
- ----- -------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
0
----- --------------------------------------------------------
NUMBER OF 6 SHARED VOTING POWER
SHARES
BENEFICIALLY 3,422,717
OWNED BY ----- --------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 0
WITH: ----- --------------------------------------------------------
8 SHARED DISPOSITIVE POWER
3,422,717
- ----- -------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,422,717
- ----- -------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [_]
- ----- -------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.3%
- ----- -------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN
================================================================================
Page 3 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 4 OF 16
==================== =============
================================================================================
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
OBP MANAGEMENT IV L.P.
- ----- -------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)(a)[_]
(b)[_]
- ----- -------------------------------------------------------------------------
3 SEC USE ONLY
- ----- -------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
0
----- --------------------------------------------------------
NUMBER OF 6 SHARED VOTING POWER
SHARES
BENEFICIALLY 3,422,717
OWNED BY ----- --------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 0
WITH: ----- --------------------------------------------------------
8 SHARED DISPOSITIVE POWER
3,422,717
- ----- -------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,422,717
- ----- -------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [_]
- ----- -------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.3%
- ----- -------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN
================================================================================
Page 4 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 5 OF 16
==================== =============
================================================================================
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
JEFFREY T BARNES
- ----- -------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)(a)[_]
(b)[_]
- ----- -------------------------------------------------------------------------
3 SEC USE ONLY
- ----- -------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
0
----- --------------------------------------------------------
NUMBER OF 6 SHARED VOTING POWER
SHARES
BENEFICIALLY 3,422,717
OWNED BY ----- --------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 0
WITH: ----- --------------------------------------------------------
8 SHARED DISPOSITIVE POWER
3,422,717
- ----- -------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,422,717
- ----- -------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [_]
- ----- -------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.3%
- ----- -------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
================================================================================
Page 5 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 6 OF 16
==================== =============
================================================================================
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
JONATHAN J. FLEMING
- ----- -------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)(a)[_]
(b)[_]
- ----- -------------------------------------------------------------------------
3 SEC USE ONLY
- ----- -------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
0
----- --------------------------------------------------------
NUMBER OF 6 SHARED VOTING POWER
SHARES
BENEFICIALLY 3,422,717
OWNED BY ----- --------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 0
WITH: ----- --------------------------------------------------------
8 SHARED DISPOSITIVE POWER
3,422,717
- ----- -------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,422,717
- ----- -------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [_]
- ----- -------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.3%
- ----- -------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
================================================================================
Page 6 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 7 OF 16
==================== =============
================================================================================
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
MICHAEL E. LYTTON
- ----- -------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)(a)[_]
(b)[_]
- ----- -------------------------------------------------------------------------
3 SEC USE ONLY
- ----- -------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
0
----- --------------------------------------------------------
NUMBER OF 6 SHARED VOTING POWER
SHARES
BENEFICIALLY 3,422,717
OWNED BY ----- --------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 0
WITH: ----- --------------------------------------------------------
8 SHARED DISPOSITIVE POWER
3,422,717
- ----- -------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,422,717
- ----- -------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [_]
- ----- -------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.3%
- ----- -------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
================================================================================
Page 7 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 8 OF 16
==================== =============
================================================================================
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
ALAN G. WALTON
- ----- -------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)(a)[_]
(b)[_]
- ----- -------------------------------------------------------------------------
3 SEC USE ONLY
- ----- -------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
59,715
----- --------------------------------------------------------
NUMBER OF 6 SHARED VOTING POWER
SHARES
BENEFICIALLY 3,422,717
OWNED BY ----- --------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 59,715
WITH: ----- --------------------------------------------------------
8 SHARED DISPOSITIVE POWER
3,422,717
- ----- -------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,482,432
- ----- -------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [_]
- ----- -------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.4%
- ----- -------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
================================================================================
Page 8 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 9 OF 16
==================== =============
ITEM 1(A). NAME OF ISSUER:
--------------
Acadia Pharmaceuticals Inc. (the "Issuer")
ITEM 1(B). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
-----------------------------------------------
3911 Sorrento Valley Boulevard, San Diego, CA 92121
ITEM 2(A). NAMES OF PERSONS FILING:
-----------------------
Oxford Bioscience Partners IV L.P. ("Oxford IV") and mRNA Fund II
L.P. ("mRNA II") (collectively, the "Funds"); OBP Management IV
L.P. ("OBP IV"), which is the sole general partner of Oxford IV and
mRNA II; and Jeffrey T. Barnes ("Barnes"), Jonathan J. Fleming
("Fleming"), Michael E. Lytton ("Lytton") and Alan G. Walton
("Walton") (collectively, the "General Partners"), who are the
general partners of OBP IV. The persons named in this paragraph are
referred to individually herein as a "Reporting Person" and
collectively as the "Reporting Persons."
ITEM 2(B). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
-----------------------------------------------------------
The address of the principal business office of Oxford IV, mRNA II,
OBP IV, Barnes, Fleming and Lytton is 222 Berkeley Street, Suite
1650, Boston, Massachusetts 02116. The address of the principal
business office of Walton is 315 Post Rd. West, Westport,
Connecticut 06880.
ITEM 2(C). CITIZENSHIP:
-----------
The Funds and OBP IV are limited partnerships organized under the
laws of the State of Delaware. Each of the General Partners is a
United States citizen.
ITEM 2(D). TITLE OF CLASS OF SECURITIES:
----------------------------
Common Stock, $.0001 par value ("Common Stock").
ITEM 2(E). CUSIP NUMBER:
------------
004225108.
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.SS. 240.13D-1(B) OR
-------------------------------------------------------------
240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
---------------------------------------------------------
Not applicable.
ITEM 4. OWNERSHIP.
(a) Amount Beneficially Owned: Oxford IV is the record owner of
3,396,738 shares of Common Stock as of December 31, 2007. mRNA
II is the record owner of 25,979 shares of Common Stock as of
December 31, 2007 (the shares held of record by Oxford IV and
mRNA II, the "Record Shares"). As the sole general partner of
Oxford IV and mRNA II, OBP IV may be deemed to own the Record
Shares. As the individual general partners of OBP IV, each of
the General Partners may also be deemed to share the power and
direct the disposition and vote of the Record Shares. In
addition, as of December 31, 2007, Walton holds the right to
options to exercise 59,715 shares of Common Stock (the "Option
Shares").
(b) Percent of Class: See Line 11 of the cover sheets. The
percentages set forth on the cover sheets for each Reporting
Person other than Walton are calculated based on 36,967,340
shares of Common Stock reported to be outstanding by the
Page 9 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 10 OF 16
==================== =============
Issuer in Form 10-Q as filed with the Securities and Exchange
Commission on November 5, 2007 for the period ending September
30, 2007 (the "Reported Shares"). Walton's percentage is
calculated based on 37,027,055 shares, which includes the
Reported Shares and the Option Shares.
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: See Line 5 of
cover sheets.
(ii) Shared power to vote or to direct the vote: See Line 6
of cover sheets.
(iii) Sole power to dispose or to direct the disposition of:
See Line 7 of cover sheets.
(iv) Shared power to dispose or to direct the disposition of:
See Line 8 of cover sheets.
Each Reporting Person disclaims beneficial ownership of such shares
of Common Stock, except for the shares, if any, such Reporting
Person holds of record.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
--------------------------------------------
Mark P. Carthy has ceased to be a general partner of OBP IV and
accordingly is no longer deemed to share the power to direct the
disposition or vote of the Record Shares.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
---------------------------------------------------------------
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
------------------------------------------------------------------
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
------------------------------------------------------------
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
---------------------------------------------------------
Not applicable. The Reporting Persons expressly disclaim membership
in a "group" as used in Rule 13d-5(b).
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
------------------------------
Not applicable.
ITEM 10. CERTIFICATION.
-------------
Not applicable. This statement on Schedule 13G is not filed
pursuant to Rule 13d-1(b) or Rule 13d-1(c).
Page 10 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 11 OF 16
==================== =============
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief,
each of the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Date: February 11, 2008
OXFORD BIOSCIENCE PARTNERS IV L.P.
By: OBP MANAGEMENT IV L.P.
General Partner
By: *
-----------------------------------
Jonathan J. Fleming
General Partner
mRNA FUND II L.P.
By: OBP MANAGEMENT IV L.P.
General Partner
By: *
-----------------------------------
Jonathan J. Fleming
General Partner
OBP MANAGEMENT IV L.P.
By: *
-----------------------------------
Jonathan J. Fleming
General Partner
*
- -----------------------------------
Jeffery T. Barnes
*
- -----------------------------------
Jonathan J. Fleming
*
- -----------------------------------
Michael E. Lytton
*
- -----------------------------------
Alan G. Walton
Page 11 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 12 OF 16
==================== =============
*By: /s/ Raymond Charest
-----------------------------------
Raymond Charest
As attorney-in-fact
This Amendment to Schedule 13G was executed by Raymond Charest on behalf of the
individuals listed above pursuant to Powers of Attorney, copies of which are
attached as Exhibit 2.
Page 12 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 13 OF 16
==================== =============
EXHIBIT 1
---------
AGREEMENT
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934,
the undersigned hereby agree that only one statement containing the information
required by Schedule 13G need be filed with respect to the ownership by each of
the undersigned of shares of stock of Acadia Pharmaceuticals Inc.
EXECUTED this 11th day of February, 2008.
OXFORD BIOSCIENCE PARTNERS IV L.P.
By: OBP MANAGEMENT IV L.P.
General Partner
By: *
-----------------------------------
Jonathan J. Fleming
General Partner
mRNA FUND II L.P.
By: OBP MANAGEMENT IV L.P.
General Partner
By: *
-----------------------------------
Jonathan J. Fleming
General Partner
OBP MANAGEMENT IV L.P.
By: *
-----------------------------------
Jonathan J. Fleming
General Partner
*
- -----------------------------------
Jeffery T. Barnes
*
- -----------------------------------
Jonathan J. Fleming
*
- -----------------------------------
Michael E. Lytton
Page 13 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 14 OF 16
==================== =============
*
- -----------------------------------
Alan G. Walton
*By: /s/ Raymond Charest
-----------------------------------
Raymond Charest
As attorney-in-fact
This Amendment to Schedule 13G was executed by Raymond Charest on behalf of the
individuals listed above pursuant to Powers of Attorney, copies of which are
attached as Exhibit 2.
Page 14 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 15 OF 16
==================== =============
EXHIBIT 2
---------
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature
appears below hereby constitutes and appoints Raymond Charest, Alexia Pearsall
and Jonathan J. Fleming, and each of them, with full power to act without the
other, his true and lawful attorney-in-fact and agent, with full power of
substitution, for him and in his name, place and stead, in any and all
capacities (until revoked in writing) to sign any and all instruments,
certificates and documents required to be executed on behalf of himself as an
individual or in his capacity as a general partner or authorized signatory, as
the case may be, on behalf of any of Oxford Bioscience Partners IV L.P., mRNA II
L.P., or OBP Management IV L.P., pursuant to section 13 or 16 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and any and all
regulations promulgated thereunder and to file the same, with all exhibits
thereto, and any other documents in connection therewith, with the Securities
and Exchange Commission, and with any other entity when and if such is mandated
by the Exchange Act or by the By-laws of the National Association of Securities
Dealers, Inc., granting unto said attorney-in-fact and agent full power and
authority to do and perform each and every act and thing requisite and necessary
fully to all intents and purposes as he might or could do in person thereby
ratifying and confirming all that said attorney-in-fact and agent, or his
substitute or substitutes, may lawfully do or cause to be done by virtue hereof,
or may have done in connection with the matters described above.
IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 8th day of
April, 2004.
OXFORD BIOSCIENCE PARTNERS IV L.P.
BY ITS GENERAL PARTNER, OBP MANAGEMENT IV L.P.
By: /s/ Jonathan Fleming
-------------------------------------------
Name: Jonathan J. Fleming
Title: General Partner
MRNA FUND II L.P.
BY ITS GENERAL PARTNER, OBP MANAGEMENT IV L.P.
By: /s/ Jonathan Fleming
-------------------------------------------
Name: Jonathan J. Fleming
Title: General Partner
OBP MANAGEMENT IV L.P.
By: /s/ Jonathan Fleming
-------------------------------------------
Name: Jonathan J. Fleming
Title: General Partner
Page 15 of 16 pages
==================== =============
CUSIP NO. 004225108 13G PAGE 16 OF 16
==================== =============
/s/ Jeffrey T. Barnes
----------------------------------------------
Jeffrey T. Barnes
/s/ Mark P. Carthy
----------------------------------------------
Mark P. Carthy
/s/ Jonathan J. Fleming
----------------------------------------------
Jonathan J. Fleming
/s/ Michael E. Lytton
----------------------------------------------
Michael E. Lytton
/s/ Alan G. Walton
----------------------------------------------
Alan G. Walton
Page 16 of 16 pages